Payment overview · 2025
General Payments
$40.12
2 reported records · 2 companies
Healthcare provider profile · identity verified
Brian R Irwin, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · TAMWORTH, NH · NPI 1427070630
Verified facts
What the public records show
CMS Open Payments records show Brian R Irwin, D.O. received $40.12 in general payments during 2025 across 2 reported records.
ABBVIE INC. accounted for 52.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $20.93 | 52.2% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $19.19 | 47.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $40.12 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $20.93 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $19.19 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 30 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
30 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Lisinopril | Lisinopril | 589 | 154 |
| Atorvastatin Calcium | Atorvastatin Calcium | 450 | 126 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 417 | 111 |
| Amlodipine Besylate | Amlodipine Besylate | 304 | 85 |
| Levothyroxine Sodium | Levothyroxine Sodium | 289 | 64 |
| Pantoprazole Sodium | Pantoprazole Sodium | 264 | 71 |
| Losartan Potassium | Losartan Potassium | 231 | 58 |
| Metoprolol Succinate | Metoprolol Succinate | 221 | 64 |
| Gabapentin | Gabapentin | 200 | 45 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 196 | 49 |
| Eliquis | Apixaban | 191 | 40 |
| Tamsulosin Hcl | Tamsulosin Hcl | 186 | 45 |
| Hydrochlorothiazide | Hydrochlorothiazide | 181 | 48 |
| Omeprazole | Omeprazole | 177 | 46 |
| Metformin Hcl | Metformin Hcl | 171 | 39 |
| Trazodone Hcl | Trazodone Hcl | 167 | 36 |
| Simvastatin | Simvastatin | 148 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 145 | 39 |
| Potassium Chloride | Potassium Chloride | 139 | 39 |
| Meloxicam | Meloxicam | 127 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 121 | 26 |
| Tramadol Hcl | Tramadol Hcl | 121 | 23 |
| Chlorthalidone | Chlorthalidone | 118 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 110 | 25 |
| Atenolol | Atenolol | 108 | 24 |
| Januvia | Sitagliptin Phosphate | 107 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 99 | 21 |
| Methylprednisolone | Methylprednisolone | 97 | 90 |
| Lorazepam | Lorazepam | 94 | 31 |
| Oxycodone Hcl | Oxycodone Hcl | 87 | 16 |
| Alprazolam | Alprazolam | 86 | 14 |
| Furosemide | Furosemide | 84 | 29 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 83 | 12 |
| Pregabalin | Pregabalin | 81 | suppressed |
| Celecoxib | Celecoxib | 80 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 74 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 74 | 27 |
| Clonazepam | Clonazepam | 72 | 14 |
| Spironolactone | Spironolactone | 67 | 18 |
| Sertraline Hcl | Sertraline Hcl | 61 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 59 | 23 |
| Carvedilol | Carvedilol | 56 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 56 | 11 |
| Montelukast Sodium | Montelukast Sodium | 54 | 14 |
| Allopurinol | Allopurinol | 52 | 17 |
| Ezetimibe | Ezetimibe | 52 | 14 |
| Aripiprazole | Aripiprazole | 51 | 14 |
| Famotidine | Famotidine | 50 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 49 | 12 |
| Bupropion Xl | Bupropion Hcl | 49 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 48 | 13 |
| Buspirone Hcl | Buspirone Hcl | 46 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 46 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 46 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 40 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 37 | suppressed |
| Diazepam | Diazepam | 36 | 11 |
| Azithromycin | Azithromycin | 35 | 35 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 35 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 35 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 35 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 34 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 33 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 33 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 32 | 13 |
| Morphine Sulfate Er | Morphine Sulfate | 32 | suppressed |
| Baclofen | Baclofen | 31 | suppressed |
| Estradiol | Estradiol | 31 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 31 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 31 | 13 |
| Tresiba Flextouch U-100 | Insulin Degludec | 31 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 30 | suppressed |
| Ozempic | Semaglutide | 30 | 11 |
| Valacyclovir | Valacyclovir Hcl | 30 | 12 |
| Alendronate Sodium | Alendronate Sodium | 29 | 11 |
| Memantine Hcl | Memantine Hcl | 28 | suppressed |
| Mirtazapine | Mirtazapine | 28 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Synthroid | Levothyroxine Sodium | 28 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 28 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 28 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 27 | suppressed |
| Glyburide | Glyburide | 27 | suppressed |
| Trulicity | Dulaglutide | 27 | suppressed |
| Jardiance | Empagliflozin | 26 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | suppressed |
| Ketoconazole | Ketoconazole | 25 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 22 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 22 | suppressed |
| Acyclovir | Acyclovir | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 18 |
| Finasteride | Finasteride | 20 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 20 | suppressed |
| Primidone | Primidone | 20 | suppressed |
| Risperidone | Risperidone | 20 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 19 | suppressed |
| Glipizide | Glipizide | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Atovaquone-Proguanil Hcl | Atovaquone/Proguanil Hcl | 18 | 16 |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 18 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 17 | suppressed |
| Fluocinolone Acetonide | Fluocinolone Acetonide | 17 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Levemir Flexpen | Insulin Detemir | 17 | suppressed |
| Prednisone | Prednisone | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 14 |
| Divalproex Sodium Er | Divalproex Sodium | 16 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | 11 |
| Lidocaine | Lidocaine | 15 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 15 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 15 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 12 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $40.12 · 2 records | ABBVIE INC. | Ozempic, VRAYLAR | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error